Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
MoneyWeek2d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 45th Annual Health Care Conference (Transcript)
Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...
BioSpace6d
Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure
Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...
Le Lézard6d
Google Cloud Enhances Vertex AI Search for Healthcare with Multimodal AI
Google Cloud today announced new generative AI (gen AI) capabilities in Vertex AI Search for healthcare, including a new feature called Visual Q&A that searches tables, charts, and diagrams, and the ...